Document Detail

Role of phosphodiesterases in adult-onset pulmonary arterial hypertension.
MedLine Citation:
PMID:  21695645     Owner:  NLM     Status:  MEDLINE    
Pulmonary arterial hypertension (PAH) is characterized by increased mean pulmonary artery pressure (mPAP) due to vasoconstriction and structural changes in the small pulmonary arteries (PAs); proliferation of pulmonary artery smooth muscle cells (PASMCs) contributes to the remodeling. The abnormal pathophysiology in the pulmonary vasculature relates to decreased cyclic nucleotide levels in PASMCs. Phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cGMP, thereby PDE inhibitors are effective in vasodilating the PA and decreasing PASMC proliferation. Experimental studies support the use of PDE3, PDE5, and PDE1 inhibitors in PAH. PDE5 inhibitors such as sildenafil are clinically approved to treat different forms of PAH and lower mPAP, increase functional capacity, and decrease right ventricular hypertrophy, without decreasing systemic arterial pressure. New evidence suggests that the combination of PDE inhibitors with other therapies for PAH may be beneficial in treating the disease. Furthermore, inhibiting PDEs in the heart and the inflammatory cells that infiltrate the PA may offer new targets to reduce right ventricular hypertrophy and inhibit inflammation that is associated with and contributes to the development of PAH. This chapter summarizes the advances in the area and the future of PDEs in PAH.
F Murray; M R Maclean; P A Insel
Related Documents :
9930415 - Determinants of 15-year outcome with 1,119 standard carpentier-edwards porcine valves.
21695645 - Role of phosphodiesterases in adult-onset pulmonary arterial hypertension.
12150305 - The bovine jugular vein: a totally integrated valved conduit to repair the right ventri...
22084605 - Asymptomatic pulmonary hypertension in systemic lupus erythematosus.
19841965 - Clinical improvement after banding of a pulmonary branch artery in a symptomatic patien...
14745625 - Pseudoaneurysm of the superior pancreaticoduodenal artery, a rare cause of hemosuccus p...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Handbook of experimental pharmacology     Volume:  -     ISSN:  0171-2004     ISO Abbreviation:  Handb Exp Pharmacol     Publication Date:  2011  
Date Detail:
Created Date:  2011-06-22     Completed Date:  2011-09-20     Revised Date:  2012-06-11    
Medline Journal Info:
Nlm Unique ID:  7902231     Medline TA:  Handb Exp Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  279-305     Citation Subset:  IM    
Department of Pharmacology and Department of Medicine, BSB 3073, University of California, 9500 Gilman Drive, La Jolla, San Diego, CA 92093-0636, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cyclic Nucleotide Phosphodiesterases, Type 1 / physiology
Hypertension, Pulmonary / drug therapy,  etiology*
Nucleotides, Cyclic / physiology
Phosphodiesterase 3 Inhibitors / therapeutic use
Phosphodiesterase 5 Inhibitors / therapeutic use
Phosphodiesterase Inhibitors / therapeutic use
Phosphoric Diester Hydrolases / physiology*
Grant Support
Reg. No./Substance:
0/Nucleotides, Cyclic; 0/Phosphodiesterase 3 Inhibitors; 0/Phosphodiesterase 5 Inhibitors; 0/Phosphodiesterase Inhibitors; EC 3.1.4.-/Phosphoric Diester Hydrolases; EC Nucleotide Phosphodiesterases, Type 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension.
Next Document:  Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.